Literature DB >> 7954437

Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.

R M Lorence1, B B Katubig, K W Reichard, H M Reyes, A Phuangsab, M D Sassetti, R J Walter, M E Peeples.   

Abstract

We have recently demonstrated that a single local injection of the avian pathogen Newcastle disease virus (NDV; strain 73-T) causes complete regression of human neuroblastoma xenografts in athymic mice (R. M. Lorence, K. W. Reichard, B. B. Katubig, H. M. Reyes, A. Phuangsab, B. R. Mitchell, C. J. Cascino, R. J. Walter, and M. E. Peeples. J. Natl. Cancer Inst., 86: 1228-1233, 1994). In this report, we tried to determine if this in vivo antineoplastic effect of NDV extends to human sarcomas. Athymic mice with s.c. HT1080 fibrosarcoma xenografts (7-14 mm) were randomly divided into two groups and treated i.t. with a single injection of either 10(7) plaque-forming units of NDV or phosphate-buffered saline. Complete tumor regression occurred in 8 of 10 mice treated with NDV while unabated tumor growth occurred in all 9 mice treated with phosphate-buffered saline (P < 0.001). To determine if complete tumor regression was long lasting, the 8 mice were monitored for 1 year, during which time no tumor recurred. To test the antitumor effects of NDV on tumors derived from a fresh human sarcoma, a similar experiment was performed in athymic mice using TH15145 synovial sarcoma xenografts at their first and second passages. Of 9 mice with TH15145 xenografts, a single i.t. injection of NDV (10(7) plaque-forming units) caused complete regression of 3 tumors and > 80% regression in 3 more tumors. In contrast, tumors in all 5 mice treated with phosphate-buffered saline exhibited unabated growth (P < 0.03 for > 80% tumor regression). Since HT1080 fibrosarcoma cells express the N-ras oncogene, we explored the effects that transfection of this oncogene has on the sensitivity to NDV. Cultured human fibroblasts that were made tumorigenic following N-ras-transfection were found to be 1000-fold more sensitive to NDV than normal fibroblasts in a cytotoxicity assay. Oncogene expression by the HT1080 fibrosarcoma may therefore contribute to the long-lasting complete regression of this sarcoma following a single local injection of NDV.

Entities:  

Mesh:

Year:  1994        PMID: 7954437

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

Review 2.  Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Authors:  Paul M Foreman; Gregory K Friedman; Kevin A Cassady; James M Markert
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 3.  Oncolytic viral therapy of malignant glioma.

Authors:  Jacqueline Nuss Parker; David F Bauer; James J Cody; James M Markert
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells.

Authors:  N Bar-Eli; H Giloh; M Schlesinger; Z Zakay-Rones
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.

Authors:  Sarah Abdullahi; Melanie Jäkel; Sabine J Behrend; Katja Steiger; Geoffrey Topping; Teresa Krabbe; Alessio Colombo; Volker Sandig; Tobias S Schiergens; Wolfgang E Thasler; Jens Werner; Stefan F Lichtenthaler; Roland M Schmid; Oliver Ebert; Jennifer Altomonte
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

6.  Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Authors:  K Ikeda; H Wakimoto; T Ichikawa; S Jhung; F H Hochberg; D N Louis; E A Chiocca
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines.

Authors:  Zsolt Fábián; Christine M Csatary; József Szeberényi; Laszlo K Csatary
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

8.  MTH-68/H oncolytic viral treatment in human high-grade gliomas.

Authors:  L K Csatary; G Gosztonyi; J Szeberenyi; Z Fabian; V Liszka; B Bodey; C M Csatary
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

10.  Anticancer oncolytic activity of respiratory syncytial virus.

Authors:  I Echchgadda; S Kota; I DeLa Cruz; A Sabbah; T Chang; R Harnack; V Mgbemena; B Chatterjee; S Bose
Journal:  Cancer Gene Ther       Date:  2009-05-15       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.